DP303c
Sponsors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Shanghai Runshi Pharmaceutical Technology Co., Ltd
Conditions
Advanced Solid TumorsDisease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the PastExpressing Human Epidermal Growth Factor Receptor-2 (HER-2)HER2-positive Advanced Breast CancerHER2-positive Advanced Solid TumorsHER2-positive Breast CancerLocalized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Phase 1
A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors
NCT05810103
Start: 2023-04-06End: 2024-03-23Target: 12Updated: 2023-04-12
A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Not yet recruitingNCT06577376
Start: 2024-08-26End: 2027-08-26Target: 252Updated: 2024-09-05
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
RecruitingNCT07241936
Start: 2025-11-13End: 2028-10-30Target: 444Updated: 2025-11-28
Phase 2
Phase 3
DP303c in Patients With HER2-positive Advanced Breast Cancer
Not yet recruitingNCT05901935
Start: 2023-07-31End: 2028-07-31Target: 420Updated: 2023-06-13
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
RecruitingNCT06313086
Start: 2024-03-13End: 2028-02-29Target: 442Updated: 2024-05-10